Safety and efficacy of an intravenous nanocrystal formulation of meloxicam in the management of moderate to severe pain following laparoscopic abdominal surgery

Abstract

Neil Singla,1 Stewart W McCallum,2 Randall J Mack,2 Alex Freyer,2 Sue Hobson,2 Wei Du3 1Lotus Clinical Research, Pasadena, CA, USA; 2Research and Development, Recro Pharma, Inc., Malvern, PA, USA; 3Clinical Statistics Consulting, Blue Bell, PA, USAPostoperative pain after laparoscopic surgery is one of the major concerns of patients. Improper pain management can be associated with varied respiratory, cardiovascular, gastrointestinal, and psychological complications. Pain after laparoscopic surgery may be transient or persistent2 and opioids have traditionally been the mainstay treatment for postoperative pain.3 Increasing evidence exists to support a multimodal treatment approach for postoperative pain that reduces opioid side effects and decreases pain intensity (PI) scores.3 A proprietary nanocrystal intravenous (NIV) formulation of the non-steroidal anti-inflammatory meloxicam, a long-acting preferential cyclooxygenase-2 inhibitor, is being evaluated with the aim of providing rapid and sustained analgesia.

Keywords

• postoperative pain
• meloxicam IV
• COX-2 inhibitor
• laparoscopic
• safety
• efficacy